Tau pathology is commonly analyzed by positron emission tomography (PET) imaging. However, recently developed cell-based techniques for analyzing tau pathogenicity may also be used to measure an early biomarker in tauopathies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Weingarten, M.D., Lockwood, A.H., Hwo, S.Y. & Kirschner, M.W. Proc. Natl. Acad. Sci. USA 72, 1858–1862 (1975).
Wortmann, M. Alzheimers Res. Ther. 4, 40 (2012).
Murray, M.E. et al. Lancet Neurol. 10, 785–796 (2011).
Small, G.W. et al. N. Engl. J. Med. 355, 2652–2663 (2006).
Fodero-Tavoletti, M.T. et al. Brain 134, 1089–1100 (2011).
Chien, D.T. et al. J. Alzheimers Dis. 34, 457–468 (2013).
Maruyama, M. et al. Neuron 79, 1094–1108 (2013).
Holmes, B.B. et al. Proc. Natl. Acad. Sci. USA 111, E4376–E4385 (2014).
Yanamandra, K. et al. Neuron 80, 402–414 (2013).
Morris, J.C. & Price, J.L. J. Mol. Neurosci. 17, 101–118 (2001).
Villemagne, V.L. et al. Eur. J. Nucl. Med. Mol. Imaging 41, 816–826 (2014).
Chien, D.T. et al. J. Alzheimers Dis. 38, 171–184 (2014).
Braak, H. & Braak, E. Acta Neuropathol. 82, 239–259 (1991).
Kfoury, N., Holmes, B.B., Jiang, H., Holtzman, D.M. & Diamond, M.I. J. Biol. Chem. 287, 19440–19451 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Cook, C., Murray, M. & Petrucelli, L. Understanding Biomarkers of Neurodegeneration: Novel approaches to detecting tau pathology. Nat Med 21, 219–220 (2015). https://doi.org/10.1038/nm.3809
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3809
